

Karen L Reckamp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6803940/publications.pdf>

Version: 2024-02-01

155
papers

16,895
citations

47006

47
h-index

14759

127
g-index

158
all docs

158
docs citations

158
times ranked

21071
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer. <i>Protein and Cell</i> , 2022, 13, 82-89.	11.0	4
2	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 72-81.	2.6	17
3	A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naïve metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 105-115.	2.3	10
4	Population pharmacokinetic and exposure-response analyses from ALTA-1: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC. <i>Clinical and Translational Science</i> , 2022, 15, 1143-1154.	3.1	7
5	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	1.1	9
6	Cancer Screening Practices Among Healthcare Workers During the COVID-19 Pandemic. <i>Frontiers in Public Health</i> , 2022, 10, 801805.	2.7	1
7	QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC). <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, QIM22-198.	4.9	0
8	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	5
9	Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 2499-2510.	2.4	2
10	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A. <i>Journal of Clinical Oncology</i> , 2022, 40, 2295-2307.	1.6	84
11	Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. <i>Drugs - Real World Outcomes</i> , 2022, 9, 333-345.	1.6	4
12	Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9014-9014.	1.6	6
13	Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9004-9004.	1.6	6
14	Characterization of MET exon 14 skipping alterations (METex14) in non-small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9122-9122.	1.6	0
15	A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9142-TPS9142.	1.6	5
16	Successful biosimilar adoption in oncology: strategic approach to system standardization.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18605-e18605.	1.6	2
17	Clinical application of precision medicine among oncologists: A case study in RET-targeted therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18705-e18705.	1.6	0
18	CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3006-3006.	1.6	17

#	ARTICLE	IF	CITATIONS
19	A phase 1/2 study of BLU-945 in patients with common activating <i>EGFR</i> -mutant non-small cell lung cancer (NSCLC): SYMPHONY trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9156-TPS9156.	1.6	6
20	Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. <i>Current Medical Research and Opinion</i> , 2022, 38, 1587-1593.	1.9	2
21	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e257-e265.	2.9	8
22	Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach. <i>Journal of Thoracic Oncology</i> , 2021, 16, 178-182.	1.1	8
23	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS449-TPS449.	1.6	2
24	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i> -Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100114.	1.1	11
25	Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1
26	Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP) Tj ETQq0 0 0 ngBT /Overlock 10 Tf		
27	Erlotinib and Onalespib Lactate Focused on <i>EGFR</i> Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). <i>Clinical Lung Cancer</i> , 2021, 22, 541-548.	2.6	8
28	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
29	Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9027-9027.	1.6	0
30	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
31	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. <i>Pharmaceutics</i> , 2021, 13, 912.	4.5	2
32	The Association between Polluted Neighborhoods and <i>TP53</i> -Mutated Non-small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1498-1505.	2.5	8
33	Amivantamab in <i>EGFR</i> Exon 20 Insertion-Mutated Non-small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	1.6	320
34	Recall of Genomic Testing Results Among Patients with Cancer. <i>Oncologist</i> , 2021, 26, e2302-e2305.	3.7	8
35	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. <i>Chest</i> , 2021, 160, 1095-1107.	0.8	23
36	Symptomology following mRNA vaccination against SARS-CoV-2. <i>Preventive Medicine</i> , 2021, 153, 106860.	3.4	7

#	ARTICLE	IF	CITATIONS
37	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. <i>Cancer Research</i> , 2021, 81, 6273-6280.	0.9	30
38	A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	6
39	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 404-415.	1.1	102
40	Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	27.0	505
41	Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. <i>Journal of Thoracic Disease</i> , 2020, 12, 5086-5095.	1.4	29
42	Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 400-408.	2.1	4
43	Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment. <i>MDM Policy and Practice</i> , 2020, 5, 238146832092220.	0.9	2
44	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	2.0	8
45	Molecular Targets Beyond the Big 3. <i>Thoracic Surgery Clinics</i> , 2020, 30, 157-164.	1.0	6
46	Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, 545-552.e1.	2.6	11
47	Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188.	2.5	7
48	Population pharmacokinetic (PK) and exposure-response analyses from the pivotal ALTA-1L study: Model-based analyses supporting the brigatinib dose in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, e21725-e21725.	1.6	2
49	A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9627-TPS9627.	1.6	2
50	The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179. <i>Journal of Clinical Oncology</i> , 2020, 38, 9032-9032.	1.6	0
51	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
52	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
53	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
54	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0

#	ARTICLE	IF	CITATIONS
55	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations. <i>Clinical Cancer Research</i> , 2019, 25, 5832-5842.	7.0	64
56	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1901-1911.	1.1	127
57	A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 138, 124-130.	2.0	77
58	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. <i>Lung Cancer</i> , 2019, 133, 136-143.	2.0	21
59	Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4691-4700.	7.0	401
60	Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI T324) (NCT01870800)	2.8	30
61	Anaplastic Lymphoma Kinase (ALK)-positive Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 337-344.	1.3	6
62	A Phase I/II Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	9.4	88
63	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 9009-9009.	1.6	74
64	Ensartinib (X-396) in ALK-Positive Non-small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 2771-2779.	7.0	141
65	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. <i>Oncologist</i> , 2018, 23, 776-781.	3.7	8
66	Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention. <i>Journal of Cancer Education</i> , 2018, 33, 557-563.	1.3	20
67	<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	3.0	8
68	Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. <i>Cancer Biology and Therapy</i> , 2018, 19, 1023-1032.	3.4	12
69	Real-World Pseudoprogression: an Uncommon Phenomenon. <i>Journal of Thoracic Oncology</i> , 2018, 13, 880-882.	1.1	15
70	The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. <i>Clinical Cancer Research</i> , 2018, 24, 6053-6065.	7.0	27
71	NCCN Guidelines Insights: Non-small Cell Lung Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 807-821.	4.9	394
72	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with <i>RET</i> -altered cancers. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102.	1.6	87

#	ARTICLE	IF	CITATIONS
73	A Multimedia Self-management Intervention to Prepare Cancer Patients and Family Caregivers for Lung Surgery and Postoperative Recovery. <i>Clinical Lung Cancer</i> , 2017, 18, e151-e159.	2.6	32
74	Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	7.0	149
75	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 556-566.	1.1	40
76	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2490-2498.	1.6	506
77	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0.784314 mgB /Over	1.7	4314
78	Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 2184-2192.	1.6	63
79	Urine test for EGFR analysis in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, S1323-S1331.	1.4	19
80	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 255-264.	4.9	335
81	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1690-1700.	1.1	256
82	The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers. <i>Lung Cancer</i> , 2016, 101, 35-39.	2.0	33
83	Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures. <i>Annals of Thoracic Surgery</i> , 2016, 101, 495-503.	1.3	33
84	Non-Small Cell Lung Cancer, Version 6.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 515-524.	4.9	323
85	Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 3298-3306.	4.1	32
86	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 123-135.	27.0	7,261
87	Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. <i>Clinical Cancer Research</i> , 2015, 21, 4321-4326.	7.0	59
88	Interdisciplinary Palliative Care for Patients With Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 758-767.	1.2	155
89	Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. <i>Targeted Oncology</i> , 2015, 10, 65-76.	3.6	29
90	Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8001-8001.	1.6	31

#	ARTICLE	IF	CITATIONS
91	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8009-8009.	1.6	27
92	Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8087-8087.	1.6	7
93	Interdisciplinary palliative care for patients with lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 130-130.	1.6	0
94	A phase 2 trial of dacomitinib (PF00299804), an oral, irreversible pan-HER (human epidermal growth) Tj ETQq0 0 0 rgBT /Overlock 1 prior chemotherapy and erlotinib. <i>Cancer</i> , 2014, 120, 1145-1154.	4.1	125
95	PGE2-Driven Expression of c-Myc and OncomiR-17-92 Contributes to Apoptosis Resistance in NSCLC. <i>Molecular Cancer Research</i> , 2014, 12, 765-774.	3.4	37
96	Future of ALK inhibition in non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2014, 15, 1047-1049.	10.7	2
97	Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8014-8014.	1.6	18
98	Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8015-8015.	1.6	7
99	Multiaim, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8120-TPS8120.	1.6	3
100	Cancers of the Respiratory System. , 2014, , 557-574.		0
101	A 75-Year-Old Man With Progressive Bronchioalveolar Carcinoma. <i>Seminars in Oncology</i> , 2013, 40, e1-e8.	2.2	1
102	Longitudinal Changes in Function, Symptom Burden, and Quality of Life in Patients with Early-Stage Lung Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 1788-1797.	1.5	35
103	Intraventricular Chemotherapy for Leptomeningeal Carcinomatosis from Lung Cancer: A Feasible and Beneficial Treatment Option?. <i>Journal of Thoracic Oncology</i> , 2013, 8, 523-524.	1.1	7
104	Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8026-8026.	1.6	17
105	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8027-8027.	1.6	22
106	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8028-8028.	1.6	28
107	Myeloid Clusters Are Associated with a Pro-Metastatic Environment and Poor Prognosis in Smoking-Related Early Stage Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e65121.	2.5	15
108	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 481-96.	0.0	13

#	ARTICLE	IF	CITATIONS
109	CCL21 Chemokine Therapy for Lung Cancer. <i>International Trends in Immunity</i> , 2013, 1, 10-15.	0.4	8
110	Phosphatidylinositol-3-Kinase Pathway. <i>Journal of Thoracic Oncology</i> , 2012, 7, S383-S384.	1.1	2
111	Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?. <i>Lancet Oncology</i> , The, 2012, 13, 435-436.	10.7	4
112	Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. <i>Cancer Letters</i> , 2012, 321, 101-109.	7.2	8
113	Predictors of finding benefit after lung cancer diagnosis. <i>Psycho-Oncology</i> , 2012, 21, 365-373.	2.3	26
114	Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies. , 2012, , 239-252.		0
115	¹⁸ F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1684-1689.	5.0	94
116	Management of non-small-cell lung cancer in the older adult. <i>Maturitas</i> , 2011, 68, 311-321.	2.4	9
117	Combination chemotherapy for older adults with advanced non-small-cell lung cancer. <i>Lancet</i> , The, 2011, 378, 1055-1057.	13.7	2
118	Novel Mechanisms and Targets; Miscellaneous Agents. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1812-S1814.	1.1	0
119	Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1741-1745.	1.1	10
120	Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung Cancer: A California Cancer Consortium Trial. <i>Clinical Lung Cancer</i> , 2011, 12, 33-37.	2.6	18
121	City of hope cancer center hematology oncology fellowship and hematopoietic stem cell transplantation fellowship. <i>American Journal of Hematology</i> , 2011, 86, 197-198.	4.1	1
122	Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apicoxib in combination with erlotinib in advanced nonsmall cell lung cancer. <i>Cancer</i> , 2011, 117, 809-818.	4.1	19
123	Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480. <i>Cancer Research</i> , 2011, 71, 6601-6610.	0.9	109
124	Consistency of a two clinical site sample collection: A proteomics study. <i>Proteomics - Clinical Applications</i> , 2010, 4, 726-738.	1.6	6
125	Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 279-290.	7.0	56
126	Targeting Stat3 in the Myeloid Compartment Drastically Improves the <i>In vivo</i> Antitumor Functions of Adoptively Transferred T Cells. <i>Cancer Research</i> , 2010, 70, 7455-7464.	0.9	118

#	ARTICLE	IF	CITATIONS
127	Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1931-1944.	4.1	74
128	Targeting STAT3 in Adoptively Transferred T Cells Promotes Their <i>In Vivo</i> Expansion and Antitumor Effects. <i>Cancer Research</i> , 2010, 70, 9599-9610.	0.9	108
129	Akt inhibitors in clinical development for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1355-1366.	4.1	202
130	STAT3: A Target to Enhance Antitumor Immune Response. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 41-59.	1.1	97
131	PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 356-67.	0.0	52
132	Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium. <i>Journal of Thoracic Oncology</i> , 2009, 4, 930-935.	1.1	0
133	CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2009, 9, 213.	2.6	34
134	Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2746-2758.	3.8	124
135	Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis. , 2009, , 249-265.		0
136	Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options. <i>Seminars in Oncology</i> , 2008, 35, 590-596.	2.2	28
137	The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 340-345.	2.6	42
138	An Interdisciplinary Care Approach for Integration of Palliative Care in Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 352-360.	2.6	36
139	A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 1355-1362.	7.0	63
140	Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-Cadherin. <i>Journal of Thoracic Oncology</i> , 2008, 3, 117-124.	1.1	56
141	Chemokines as therapeutic targets in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 887-893.	2.4	22
142	Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance. <i>Journal of Thoracic Oncology</i> , 2008, 3, 107-110.	1.1	50
143	Inflammation and lung carcinogenesis: applying findings in prevention and treatment. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1405-1421.	2.4	71
144	Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy. <i>Journal of Immunotherapy</i> , 2007, 30, 417-424.	2.4	30

#	ARTICLE	IF	CITATIONS
145	Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. <i>Molecular Cancer</i> , 2006, 5, 56.	19.2	147
146	The Potential and Rationale for COX-2 Inhibitors in Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2006, 6, 209-220.	1.7	77
147	A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3381-3388.	7.0	111
148	Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. <i>Cancer Research</i> , 2006, 66, 3205-3213.	0.9	82
149	PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. <i>Journal of Leukocyte Biology</i> , 2005, 78, 555-564.	3.3	40
150	Prostaglandin E2 Induces <i>FOXP3</i> Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells. <i>Journal of Immunology</i> , 2005, 175, 1483-1490.	0.8	543
151	Cyclooxygenase 2 Inhibition Promotes IFN- γ -Dependent Enhancement of Antitumor Responses. <i>Journal of Immunology</i> , 2005, 175, 813-819.	0.8	73
152	Prostaglandin E2 Activates Mitogen-Activated Protein Kinase/Erk Pathway Signaling and Cell Proliferation in Nonâ€“Small Cell Lung Cancer Cells in an Epidermal Growth Factor Receptorâ€“Independent Manner. <i>Cancer Research</i> , 2005, 65, 6275-6281.	0.9	207
153	The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma. <i>Journal of Immunology</i> , 2005, 175, 5351-5357.	0.8	133
154	Chemoprevention Strategies with Cyclooxygenase-2 Inhibitors for Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, 30-39.	2.6	42
155	Tumor Cyclooxygenase-2/Prostaglandin E2â€“Dependent Promotion of FOXP3 Expression and CD4+CD25+ T Regulatory Cell Activities in Lung Cancer. <i>Cancer Research</i> , 2005, 65, 5211-5220.	0.9	452